---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-23-000026"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:40:30.578694+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M

## Summary
- Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).
- Record H1 2023 revenues of $1.19B (+13% YoY); VOXZOGO Q2 sales surged 229% to $113.3M.
- Full-year VOXZOGO revenue guidance raised to $400-440M (was $380-430M); GAAP net income guidance raised to $165-215M.
- US approved ROCTAVIAN on June 29; commercial launch started; European reimbursement negotiations continue.
- Pivotal program for VOXZOGO in hypochondroplasia to begin in Q4 2023; ongoing studies for age expansion and pipeline updates.

## SEC filing metadata
- accession: 0001048477-23-000026
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/0001048477-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/bmrn-20230731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-23-000026
- JSON: https://secwatch.observer/filing/0001048477-23-000026.json
- Plain text: https://secwatch.observer/filing/0001048477-23-000026.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC updated its the six months and second quarter ended June 30, 2023 guidance (reaffirmed).
  - Period: the six months and second quarter ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On July 31, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847723000026/0001048477-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.